Revlimid: Ph III Myeloma XI data

Data from 1,551 evaluable patients with newly diagnosed MM in the open-label, U.K. Phase III Myeloma XI trial showed that maintenance treatment with once-daily 10 mg oral Revlimid for 21 days

Read the full 311 word article

User Sign In